Neurocrine Biosciences Patent-Cliff Exposure & CMS Drug Spending Portfolio

Neurocrine Biosciences (San Diego, CA): 6 reconciled FDA prescription therapies, $2.56B 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterSan Diego, CA
Reconciled FDA Portfolio Therapies6
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2035-01-01
2024 CMS Total Public Spend$2.56B
2024 Medicare Part D Spend$1.97B
2024 Medicaid Spend$591.3M
California HCAI SB 17 Filings4 WAC filings (max 17.2% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Neurocrine Biosciences across sibling Meru public-data platforms.